After two doses of the BNT162b2 vaccine, virus-specific antibodies and T cells were reduced in patients with solid tumors as compared to individuals without cancer, but neutralizing antibodies increased in most patients who received a third vaccine dose.
- Rachna T. Shroff
- Pavani Chalasani
- Deepta Bhattacharya